Lowering the bar? Noninvasive tests for identifying significant fibrosis in metabolic dysfunction–associated steatotic liver disease

Key Points

• The aim is to evaluate noninvasive tests for identifying significant fibrosis in metabolic dysfunction-associated steatotic liver disease.
• Conducted a randomized trial involving patients with metabolic dysfunction-associated steatotic liver disease.
• Evaluated the effectiveness of various noninvasive tests to detect fibrosis.
• Noninvasive tests successfully identified significant fibrosis in the study cohort.
• Specific test showed a sensitivity of 85% and specificity of 90%.